Skip to main content

Peer Review reports

From: Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)

Original Submission
3 Dec 2024 Submitted Original manuscript
17 Dec 2024 Reviewed Reviewer Report
18 Dec 2024 Reviewed Reviewer Report
26 Dec 2024 Reviewed Reviewer Report
8 Jan 2025 Author responded Author comments - Zhanshuo Xiao
Resubmission - Version 2
8 Jan 2025 Submitted Manuscript version 2
9 Jan 2025 Author responded Author comments - Zhanshuo Xiao
Resubmission - Version 3
9 Jan 2025 Submitted Manuscript version 3
6 Feb 2025 Author responded Author comments - Zhanshuo Xiao
Resubmission - Version 4
6 Feb 2025 Submitted Manuscript version 4
6 Feb 2025 Author responded Author comments - Zhanshuo Xiao
Resubmission - Version 5
6 Feb 2025 Submitted Manuscript version 5
19 Mar 2025 Author responded Author comments - Zhanshuo Xiao
Resubmission - Version 6
19 Mar 2025 Submitted Manuscript version 6
21 Mar 2025 Author responded Author comments - Zhanshuo Xiao
Resubmission - Version 7
21 Mar 2025 Submitted Manuscript version 7
Publishing
24 Mar 2025 Editorially accepted
31 Mar 2025 Article published 10.1186/s40360-025-00912-4

You can find further information about peer review here.

Back to article page